Innovating Human Evolution, Empowering Longevity
News //
De Novo lands funding to accelerate commercialization of longevity-linked protein
August 20, 2024
Food technology company De Novo Foodlabs has secured new investment to advance its mission to develop animal-free, protein-based ingredients supporting functional nutrition. The new funding is intended to accelerate the commercialization of its flagship product, NanoFerrin, a precision-fermented version of lactoferrin.
My take on this: Lactoferrin, a protein in cow’s first milk, supports immune function, brain health and digestion. It may also help combat aging with its anti-inflammatory and antioxidant properties.
The global lactoferrin market was valued at $773 million in 2023 and is projected to grow at an annual rate of 15.8% over the next decade, however, according to De Novo, the traditional extraction of lactoferrin from milk is not only expensive but also faces supply limitations and presents ethical and environmental concerns. The company leverages machine learning, biopharma discovery models and precision fermentation technology to produce NanoFerrin, a nature-identical protein, offering a cost-effective, sustainable alternative to bovine-sourced lactoferrin.
NanoFerrin mirrors the natural properties of lactoferrin but offers the advantages of consistency, scalability and lower production costs, which De Novo is betting will appeal to food and beverage manufacturers as well as supplement providers.
“The lactoferrin market has long been hindered by high prices and inconsistent supply,” said Jean Louwrens, CEO of De Novo. “NanoFerrin is not only more affordable and eco-friendly; importantly, it also provides a reliable supply source compared to traditional bovine lactoferrin products.”
ThermoFace: Revealing Biological Age and Hidden Health Risks via Your Face's Heat Map
Aug. 19, 2024
Researchers at Peking University introduced "ThermoFace," a non-invasive diagnostic tool that uses thermal facial imaging to assess biological age and predict metabolic diseases like diabetes and hypertension, showing promise as a rapid, cost-effective method for early disease detection and monitoring.
https://www.biopharmatrend.com/post/914-thermoface-revealing-biological-age-and-hidden-health-risks-via-your-faces-heat-map/?utm_source=substack&utm_medium=email
Text-to-speech brain implant restores ALS patient's voice.
August 15, 2024
Blackrock Neurotech, backed by Tether, has enabled an ALS patient to regain speech using a brain-computer interface (BCI) that translates thoughts into spoken words at 62 words per minute, marking a significant milestone in neurological technology.
https://www.reuters.com/business/healthcare-pharmaceuticals/text-to-speech-brain-implant-restores-als-patients-voice-2024-08-14/?utm_source=substack&utm_medium=email
Aging and Longevity
We are pioneering research in the field of aging and longevity with the goal of extending healthy human lifespan. Our work focuses on understanding the fundamental biological processes that drive aging and how these can be modulated to prevent age-related diseases and promote regenerative health.
By leveraging cutting-edge technologies and AI in cellular regeneration, genetics, and epigenetics, we aim to develop innovative therapies that not only slow the aging process but also enhance the quality of life during the later years. Our commitment is to bring scientific breakthroughs from the lab to real-world applications, offering hope for a healthier, more vibrant future for people of all ages.
Cellular Regeneration and Stem Cell Research
We are at the forefront of cellular regeneration and stem cell research, exploring the potential of these powerful biological tools to repair and regenerate damaged tissues and organs. Our research focuses on harnessing the capabilities of stem cells to replace or restore function in cells affected by injury, disease, or aging.
By understanding and manipulating the pathways that govern cell growth and differentiation, we aim to develop groundbreaking therapies that can regenerate tissues, heal injuries, and combat degenerative conditions. Our work holds the promise of unlocking new possibilities for treatment, offering patients innovative solutions that were once thought to be science fiction.
Cancer Research
We are at the cutting edge of cancer research, utilizing a combination of advanced technologies and innovative therapies to develop more effective and personalized treatments.
Our research leverages the power of artificial intelligence (AI) to analyze complex data sets, predict treatment responses, and identify novel therapeutic targets. We are deeply invested in immunotherapy, including CAR T-cell therapy, which harnesses the patient’s own immune system to target and destroy cancer cells.
In addition, we explore the potential of gene therapy, such as CRISPR-Cas9 for precise genetic editing, and oncolytic virus therapy, which uses engineered viruses to selectively kill cancer cells. Our targeted therapies include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, aimed at disrupting the specific pathways cancer cells rely on.
We also employ radiotherapy innovations like proton beam therapy for precision targeting, and nanotechnology, including nanoparticles for drug delivery and quantum dots for enhanced imaging.
Through precision medicine, genomic profiling, and adoptive cell transfer techniques, we tailor treatments to the unique genetic makeup of each patient’s cancer.
Our holistic approach to cancer research integrates these cutting-edge tools to push the boundaries of what’s possible in oncology, with the goal of improving outcomes and enhancing the quality of life for patients worldwide.
More life - Decoding the secret of aging | DW Documentary
Lifespan, can it be altered? Can aging be reversed?
In our efforts to treat diseases, we often focus on using drugs to alleviate symptoms or manage conditions. However, shouldn't we delve deeper into understanding what fundamentally causes these diseases and tackle the root of the problem instead?
Every organism seems to have its own "expiration date": a mouse lives about 5 years, a dog around 15 years, a human 122 years, and some whales and sharks up to 500 years. This lifespan variation suggests that each species has a different timeline allocated to its cell cycle. But could this natural timeline be altered? What are the factors that determine lifespan differences across species, and is it possible to modify these factors to extend life? Understanding the underlying biological mechanisms could unlock new possibilities for changing how long we live and how we age.
Can we reverse aging?
Longevity: Can It Be Reversed?
What if aging could be slowed down or even reversed? Recent advances in biotechnology, genetics, and medicine are pushing the boundaries of what we know about aging, exploring the possibility of extending human lifespan and enhancing health as we grow older.
The science of longevity aims to uncover the mechanisms behind aging and develop therapies to mitigate its effects.In this video, leading scientists and innovators delve into groundbreaking research on how lifestyle changes, medical interventions, and cutting-edge technologies are paving the way for a future where aging may no longer be an inevitable decline.
Join us in exploring how the science of longevity is transforming our understanding of life, health, and the pursuit of a longer, healthier existence.
How close are we to being healthy indefinetly?
Rare Diseases
Our efforts focus on diseases such as Duchenne Muscular Dystrophy (DMD), Huntington’s Disease, Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Gaucher Disease, and Cystic Fibrosis (CF). We are also pioneering research in rare cancers like Glioblastoma Multiforme, as well as in conditions like Rett Syndrome, Fabry Disease, and various Lysosomal Storage Disorders (LSDs).
Through the use of cutting-edge technologies like gene therapy, CRISPR-Cas9, stem cell therapy, and precision medicine, we aim to uncover new therapeutic avenues and provide hope to patients who have historically had limited treatment options.
Our research is driven by a passion for making a tangible difference in the lives of those affected by these rare and often devastating conditions.
We are deeply committed to advancing research in the field of rare diseases, targeting some of the most challenging and underserved conditions.
Clinical Trials
We offer comprehensive clinical trial services that leverage the unique opportunities available in Mexico, including cost efficiency, favorable regulatory frameworks, and access to a diverse and wide-ranging sample population. Mexico's healthcare landscape allows us to conduct high-quality clinical trials at a fraction of the cost compared to other regions, without compromising on the rigor and standards required for global regulatory approval.
Our strategic presence in both Mexico and the United States enables us to design and execute trials that benefit from the diverse genetic backgrounds and disease profiles found in Mexico, while seamlessly integrating these findings with data from trials conducted in other countries.
This cross-border approach enhances the robustness of our research, accelerates the development of new therapies, and ultimately brings innovative treatments to market more quickly and efficiently. Whether for rare diseases, cancer, or regenerative medicine, our clinical trial capabilities are designed to meet the needs of pharmaceutical companies, research institutions, and biotech innovators worldwide.
Robotics, Organ & Tissue Engineering, and Commercializing Medicine
Our primary focus is on advancing research in cellular regeneration, aging, cancer, and rare diseases. However, we are also involved in innovative projects in robotics and organ & tissue engineering.
These initiatives explore the development of robotic systems to enhance precision in medical procedures and the engineering of tissues and organs for transplantation and regenerative medicine.
While these areas are not our central focus, we believe in their transformative potential for the future of healthcare.
Alongside these projects, we are committed to the commercialization of new medicines and technologies. Our comprehensive approach includes market analysis, clinical trial design, and regulatory compliance to ensure that our scientific advancements transition smoothly from research to real-world applications.
By integrating these efforts, we aim to bridge the gap between innovation and patient access, making a meaningful impact on global health through both pioneering research and effective commercialization strategies.